Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Abroad (travel likely)Recruiting
Conditions
Ultomiris-exposed Pregnant/ Postpartum · Pregnancy · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Atypical Hemolytic Uremic Syndrome (aHUS) · Generalized Myasthenia Gravis (gMG) · Neuromyelitis Optica Spectrum Disorder (NMOSD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Boston, Massachusetts, United States
Research Site, Melbourne, Victoria, Australia
Contact: Principal Investigator (Dr. Jeff Szer)Research Site, Paris, France
Contact: Principal Investigator (Dr Flore Sicre de Fontbrune)Research Site, Essen, Norte-Westfalia, Germany
Contact: Principal Investigator (Prof. Dr. Alexander Röth)Research Site, Rome, Italy
Contact: Principal Investigator (Doctor Simona Sica)Research Site, Seoul, South Korea
Research Site, London, United Kingdom
Study leads
Sydney Williams
Principal Investigator
North American Coordinating Center (NACC)